UnitedHealth Group (NYSE:UNH) Stock Gets Price Target Cut from Barclays

UnitedHealth Group (NYSE:UNH) had its target price cut by Barclays from $441.00 to $440.00 in a report released on Wednesday morning,Benzinga reports. They currently have an overweight rating on the healthcare conglomerate’s stock.

Several other brokerages have also recently weighed in on UNH. Piper Sandler increased their target price on UnitedHealth Group from $477.00 to $499.00 and gave the company an “overweight” rating in a report on Friday, July 17th. Mizuho boosted their price objective on UnitedHealth Group from $470.00 to $493.00 and gave the company an “outperform” rating in a research report on Monday, July 20th. Robert W. Baird dropped their price objective on UnitedHealth Group from $453.00 to $427.00 and set a “neutral” rating for the company in a research note on Wednesday. JPMorgan Chase & Co. raised their target price on shares of UnitedHealth Group from $466.00 to $516.00 and gave the stock an “overweight” rating in a report on Tuesday, July 21st. Finally, Cantor Fitzgerald lifted their target price on shares of UnitedHealth Group from $440.00 to $495.00 and gave the stock an “overweight” rating in a research note on Friday, July 17th. Twenty equities research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $462.90.

UnitedHealth Group Price Performance

Shares of NYSE:UNH opened at $401.77 on Wednesday. The company has a quick ratio of 0.78, a current ratio of 0.74 and a debt-to-equity ratio of 0.66. The stock has a market cap of $360.62 billion, a PE ratio of 19.92, a PEG ratio of 1.47 and a beta of 0.60. The company’s fifty day moving average is $387.07 and its 200 day moving average is $384.64. UnitedHealth Group has a 52 week low of $255.96 and a 52 week high of $461.62.

UnitedHealth Group (NYSE:UNH) last posted its quarterly earnings results on Tuesday, October 13th. The healthcare conglomerate reported $4.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.14 by $0.55. UnitedHealth Group had a net margin of 3.53% and a return on equity of 17.95%. The business had revenue of $112.70 billion during the quarter, compared to analyst estimates of $111.31 billion. During the same period in the prior year, the business posted $2.59 earnings per share. The company’s revenue was down .4% on a year-over-year basis. UnitedHealth Group has set its FY 2026 guidance at 20.500- EPS. Research analysts anticipate that UnitedHealth Group will post 20.65 earnings per share for the current year.

UnitedHealth Group Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 22nd. Investors of record on Monday, September 14th were paid a $2.32 dividend. The ex-dividend date of this dividend was Monday, September 14th. This represents a $9.28 annualized dividend and a dividend yield of 2.3%. UnitedHealth Group’s dividend payout ratio (DPR) is presently 53.00%.

Insider Activity

In related news, CEO Patrick Conway sold 1,169 shares of the business’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $390.00, for a total transaction of $455,910.00. Following the transaction, the chief executive officer owned 15,328 shares in the company, valued at $5,977,920. The trade was a 7.09% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.19% of the stock is owned by insiders.

Institutional Investors Weigh In On UnitedHealth Group

Large investors have recently made changes to their positions in the business. PineStone Asset Management Inc. boosted its holdings in UnitedHealth Group by 2.6% in the third quarter. PineStone Asset Management Inc. now owns 828,322 shares of the healthcare conglomerate’s stock valued at $304,060,000 after acquiring an additional 20,800 shares in the last quarter. Cravens & Co Advisors LLC raised its holdings in UnitedHealth Group by 4.3% in the 3rd quarter. Cravens & Co Advisors LLC now owns 2,448 shares of the healthcare conglomerate’s stock worth $899,000 after purchasing an additional 102 shares in the last quarter. Kintegral Advisory LLC lifted its position in shares of UnitedHealth Group by 0.6% in the 3rd quarter. Kintegral Advisory LLC now owns 7,637 shares of the healthcare conglomerate’s stock worth $2,803,000 after purchasing an additional 43 shares during the period. Intergy Private Wealth LLC boosted its stake in shares of UnitedHealth Group by 9.1% during the 3rd quarter. Intergy Private Wealth LLC now owns 693 shares of the healthcare conglomerate’s stock valued at $254,000 after purchasing an additional 58 shares in the last quarter. Finally, RKL Wealth Management LLC increased its position in shares of UnitedHealth Group by 4.8% during the third quarter. RKL Wealth Management LLC now owns 2,066 shares of the healthcare conglomerate’s stock valued at $758,000 after buying an additional 95 shares during the period. 87.86% of the stock is currently owned by institutional investors.

UnitedHealth Group News Roundup

Here are the key news stories impacting UnitedHealth Group this week:

• Positive Sentiment: Q3 results and guidance exceeded expectations. UnitedHealth reported adjusted earnings of $4.69 per share versus the $4.14 consensus estimate, while revenue of $112.7 billion also topped forecasts. Management raised its 2026 adjusted EPS outlook to at least $20.50, supporting the recovery narrative. UnitedHealth Stock Moves Higher: What’s Going On?
• Positive Sentiment: Analyst support remains significant. JPMorgan raised its price target to $524 and maintained an “overweight” rating, while Goldman Sachs reportedly lifted its target to $506 after concluding that Medicare Advantage margin recovery is progressing faster than expected. JPMorgan Raises UnitedHealth Price Target
• Positive Sentiment: Potential growth areas could support 2027 and beyond. UnitedHealth’s focus on Medicare special-needs plans, expanded coverage and care-delivery operations may provide targeted growth while improving margins. Its low beta also makes UNH attractive as a defensive healthcare holding during inflation and market rotation away from technology stocks. Can UNH’s Focus on Special Needs Plans Strengthen Medicare Growth?
• Neutral Sentiment: Recent gains may have already priced in much of the good news. Commentary noted that the earnings beat and outlook increase were followed by questions about how durable the recovery will be, limiting the immediate upside despite bullish targets. UnitedHealth Beats on Earnings, But Investors Question Growth Path
• Negative Sentiment: Membership fell and medical costs remain high. Analysts are concerned that shrinking membership and elevated utilization could constrain revenue growth and margins, particularly if higher care costs persist. This is the main reason investors are questioning whether the earnings improvement can continue. UnitedHealth’s Q3 Margins Improve, But Membership Falls
• Negative Sentiment: Analyst views are mixed. Barclays issued a pessimistic forecast, Robert W. Baird cut its price target, and TD Cowen reiterated a “hold” rating with a $402 target, signaling limited near-term upside for some investors.

UnitedHealth Group Company Profile

UnitedHealth Group Incorporated (NYSE: UNH) is a diversified health care and well-being company serving individuals, employers, health care providers and government programs. Its operations are organized primarily through UnitedHealthcare and Optum.

UnitedHealthcare provides health benefit plans and services, including employer-sponsored coverage, individual and family plans, Medicare and Medicaid offerings, and other government-supported programs. Its services include health insurance administration, pharmacy benefits and care management.

Optum provides health care services, technology and data solutions, pharmacy services, and analytics to health plans, employers, government agencies, health care providers and consumers.